These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934 [TBL] [Abstract][Full Text] [Related]
24. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. Raimondi A; Randon G; Sepe P; Claps M; Verzoni E; de Braud F; Procopio G Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480348 [TBL] [Abstract][Full Text] [Related]
25. Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. Park HJ; Kim KW; Pyo J; Suh CH; Yoon S; Hatabu H; Nishino M Radiology; 2020 Oct; 297(1):87-96. PubMed ID: 32749204 [TBL] [Abstract][Full Text] [Related]
26. Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence. Kim N; Lee ES; Won SE; Yang M; Lee AJ; Shin Y; Ko Y; Pyo J; Park HJ; Kim KW Korean J Radiol; 2022 Nov; 23(11):1089-1101. PubMed ID: 36098343 [TBL] [Abstract][Full Text] [Related]
27. Novel patterns of response under immunotherapy. Borcoman E; Kanjanapan Y; Champiat S; Kato S; Servois V; Kurzrock R; Goel S; Bedard P; Le Tourneau C Ann Oncol; 2019 Mar; 30(3):385-396. PubMed ID: 30657859 [TBL] [Abstract][Full Text] [Related]
28. Pitfalls in the radiological response assessment of immunotherapy. Beer L; Hochmair M; Prosch H Memo; 2018; 11(2):138-143. PubMed ID: 29983829 [TBL] [Abstract][Full Text] [Related]
29. Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. Vrankar M; Unk M Radiol Oncol; 2018 Oct; 52(4):365-369. PubMed ID: 30367809 [TBL] [Abstract][Full Text] [Related]
30. Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer. Doumas S; Foukas PG; Economopoulou P; Kotsantis I; Psyrri A Oral Oncol; 2020 Jan; 100():104477. PubMed ID: 31837533 [TBL] [Abstract][Full Text] [Related]
31. [Monitoring of immunotherapy : Possibilities and limitations]. Schneider H; Illert AL; Bamberg F; Eisenblätter M Radiologe; 2020 Aug; 60(8):711-720. PubMed ID: 32710153 [TBL] [Abstract][Full Text] [Related]
32. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Unterrainer M; Ruzicka M; Fabritius MP; Mittlmeier LM; Winkelmann M; Rübenthaler J; Brendel M; Subklewe M; von Bergwelt-Baildon M; Ricke J; Kunz WG; Cyran CC Eur Radiol Exp; 2020 Nov; 4(1):63. PubMed ID: 33200246 [TBL] [Abstract][Full Text] [Related]
33. Patterns of Response and Progression to Immunotherapy. Borcoman E; Nandikolla A; Long G; Goel S; Le Tourneau C Am Soc Clin Oncol Educ Book; 2018 May; 38():169-178. PubMed ID: 30231380 [TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. Wang GX; Kurra V; Gainor JF; Sullivan RJ; Flaherty KT; Lee SI; Fintelmann FJ Radiographics; 2017; 37(7):2132-2144. PubMed ID: 29131763 [TBL] [Abstract][Full Text] [Related]
35. iRECIST and atypical patterns of response to immuno-oncology drugs. Ramon-Patino JL; Schmid S; Lau S; Seymour L; Gaudreau PO; Li JJN; Bradbury PA; Calvo E J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35715004 [TBL] [Abstract][Full Text] [Related]
36. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Hodi FS; Ballinger M; Lyons B; Soria JC; Nishino M; Tabernero J; Powles T; Smith D; Hoos A; McKenna C; Beyer U; Rhee I; Fine G; Winslow N; Chen DS; Wolchok JD J Clin Oncol; 2018 Mar; 36(9):850-858. PubMed ID: 29341833 [TBL] [Abstract][Full Text] [Related]
37. Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma. Weiss J; Notohamiprodjo M; Bedke J; Nikolaou K; Kaufmann S Curr Opin Urol; 2018 Jan; 28(1):35-41. PubMed ID: 29083998 [TBL] [Abstract][Full Text] [Related]
38. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Kim HK; Heo MH; Lee HS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Cancer Chemother Pharmacol; 2017 Sep; 80(3):591-598. PubMed ID: 28733892 [TBL] [Abstract][Full Text] [Related]
39. iRECIST: how to do it. Persigehl T; Lennartz S; Schwartz LH Cancer Imaging; 2020 Jan; 20(1):2. PubMed ID: 31900236 [TBL] [Abstract][Full Text] [Related]
40. [Response criteria for malignant melanoma: RECIST and irRC]. Spiro J; Maintz D; Persigehl T Radiologe; 2015 Feb; 55(2):127-35. PubMed ID: 25637198 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]